Table 3 Comparison of patients with proportion of days covered (PDC) with antiosteoporosis medication higher and lower than 80%.
From: Long-term persistence of treatment after hip fracture in a fracture liaison service
PDC < 80 | PDC > 80 | OR (95% CI) | p | Model OR (95% CI) | p | |
|---|---|---|---|---|---|---|
(n = 164) | (n = 208) | |||||
Age (years), mean (SD) | 79.1 (9.5) | 79.5 (8.4) | 1.01 (0.98–1.03) | 0.52 | ||
Sex (female), n (%) | 110 (67.0) | 173 (83.1) | 2.43 (1.49–3.95) | 0.0001 | 1.12 (0.62–2.23) | 0.568 |
Identification of patients (ref emergency registry), n (%) | ||||||
Admission (hip fracture) | 47 (28.6) | 82 (39.4) | 1.76 (1.13–2.75) | 2.26 (1.18–4.34) | 0.014 | |
Previous fracture, n (%) | 26 (15.8) | 51 (24.5) | 1.72 (1.02–2.91) | 0.04 | ||
Previous treatment with bisphosphonates, n (%)a | 8 (4.8) | 45 (21.6) | 5.38 (2.46–11.78) | 0.0001 | 3.38 (1.34–8.54) | 0.01 |
Densitometry result; osteoporosis, n (%)a | 55 (33.5) | 59 (28.3) | 1.30 (0.75–2.26) | 0.28 | ||
Lumbar T score mean (SD) | − 1.856 (1.701) | − 1.933 (1.603) | 0.97 (0.82–1.15) | 0.74 | ||
FRAX major, mean (SD) | 16.4 (10.2) | 19.9 (10.0) | 1.04 (1.01–1.06) | 0.001 | ||
Referral to primary care after baseline visit, n (%)a | 143 (87.1) | 172 (82.6) | 0.70 (0.39–1.26) | 0.23 | ||
Start denosumab vs bisphosphonates | 14 (8.5) | 86 (41.3) | 3.07 (1.61–5.84) | 0.0001 | 2.70 (1.38–5.27) | 0.004 |
